Article info

Download PDFPDF

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Free

Authors

  1. Correspondence to Dr Domenica Lorusso, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; domenica.lorusso{at}policlinicogemelli.it
View Full Text

Citation

Clamp AR, Lorusso D, Oza AM, et al
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

Publication history

  • Received November 9, 2020
  • Revision received April 20, 2021
  • Accepted April 26, 2021
  • First published June 8, 2021.
Online issue publication 
January 10, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.